MedTrace Logo

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

NCT05567055 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-06-17

No results posted yet for this study

Summary

This is a phase II single-arm open label trial to evaluate the intracranial efficacy of capmatinib in advanced stage NSCLC with asymptomatic BM with positive MET amplification or METΔex14 detected on cfDNA.

Conditions

Interventions

DRUG

Capmatinib

Capmatinib is a medication for the treatment of metastatic non-small cell lung cancer tumors that have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Timothy Burns, MD, PHD

    lead OTHER

Principal Investigators

  • Timothy F Burns, MD, PhD · UPMC Hillman Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-03
Primary Completion
2026-09-30
Completion
2028-09-30
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05567055 on ClinicalTrials.gov